

# ONWARD Medical Announces Release of 2024 Annual Report

**EINDHOVEN, the Netherlands — April 28, 2025** — ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that its Annual Report for the fiscal year ended December 31, 2024 has been filed with the Dutch Authority for the Financial Markets (AFM).

The Company has also released its 2024 Sustainability Report. Last year, the Company was awarded a silver medal by EcoVadis, the world's largest provider of business sustainability ratings.

"2024 was transformative for ONWARD as we advanced our mission to restore movement, function, and independence for people with spinal cord injury," said Dave Marver, Chief Executive Officer. "We are pleased to share our progress and financial results with our stakeholders through our Annual Report."

The 2024 Annual Report, 2024 Sustainability Summary, and a recording of the 2024 Full Year Results Webinar held on April 1, 2025 can be viewed by visiting the Company's [Investor Relations webpage](#).

## About ONWARD Medical

ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with SCI and other movement disabilities. Building on more than a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). The Company's ARC-EX System is cleared for commercial sale in the US. In addition, the Company is developing an investigational implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).

Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY).

For more information, visit [ONWD.com](https://onwd.com) and connect with us on [LinkedIn](#) and [YouTube](#).

To be kept informed about the Company's technologies, research studies, and the availability of therapies in your area, please [complete this webform](#).

For Media Inquiries:  
[media@onwd.com](mailto:media@onwd.com)

For Investor Inquiries:  
[investors@onwd.com](mailto:investors@onwd.com)

**Disclaimer**

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.